Advancements in Personalized CAR-T Therapy: Comprehensive Overview of Biomarkers and Therapeutic Targets in Hematological Malignancies

被引:0
|
作者
Olejarz, Wioletta [1 ,2 ]
Sadowski, Karol [1 ,2 ,3 ]
Szulczyk, Daniel [4 ]
Basak, Grzegorz [3 ]
机构
[1] Med Univ Warsaw, Fac Pharm, Dept Biochem & Pharmacogen, PL-02097 Warsaw, Poland
[2] Med Univ Warsaw, Ctr Preclin Res, PL-02097 Warsaw, Poland
[3] Med Univ Warsaw, Dept Hematol Transplantat & Internal Med, PL-02097 Warsaw, Poland
[4] Med Univ Warsaw, Chair & Dept Biochem, PL-02097 Warsaw, Poland
关键词
CAR-T; EVs; immunotherapy; biomarkers; hematological malignancies; checkpoint inhibitors; TME; ACUTE LYMPHOBLASTIC-LEUKEMIA; MINIMAL RESIDUAL DISEASE; EPSTEIN-BARR-VIRUS; CELL-FREE DNA; CIRCULATING TUMOR DNA; NON-HODGKIN-LYMPHOMA; INHIBITORY RECEPTORS; IMMUNE MICROENVIRONMENT; GENE REARRANGEMENTS; MULTIPLE-MYELOMA;
D O I
10.3390/ijms25147743
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chimeric antigen receptor T-cell (CAR-T) therapy is a novel anticancer therapy using autologous or allogeneic T-cells. To date, six CAR-T therapies for specific B-cell acute lymphoblastic leukemia (B-ALL), non-Hodgkin lymphomas (NHL), and multiple myeloma (MM) have been approved by the Food and Drug Administration (FDA). Significant barriers to the effectiveness of CAR-T therapy include cytokine release syndrome (CRS), neurotoxicity in the case of Allogeneic Stem Cell Transplantation (Allo-SCT) graft-versus-host-disease (GVHD), antigen escape, modest antitumor activity, restricted trafficking, limited persistence, the immunosuppressive microenvironment, and senescence and exhaustion of CAR-Ts. Furthermore, cancer drug resistance remains a major problem in clinical practice. CAR-T therapy, in combination with checkpoint blockades and bispecific T-cell engagers (BiTEs) or other drugs, appears to be an appealing anticancer strategy. Many of these agents have shown impressive results, combining efficacy with tolerability. Biomarkers like extracellular vesicles (EVs), cell-free DNA (cfDNA), circulating tumor (ctDNA) and miRNAs may play an important role in toxicity, relapse assessment, and efficacy prediction, and can be implicated in clinical applications of CAR-T therapy and in establishing safe and efficacious personalized medicine. However, further research is required to fully comprehend the particular side effects of immunomodulation, to ascertain the best order and combination of this medication with conventional chemotherapy and targeted therapies, and to find reliable predictive biomarkers.
引用
下载
收藏
页数:23
相关论文
共 50 条
  • [1] The journey of CAR-T therapy in hematological malignancies
    Junru Lu
    Guan Jiang
    Molecular Cancer, 21
  • [2] The journey of CAR-T therapy in hematological malignancies
    Lu, Junru
    Jiang, Guan
    MOLECULAR CANCER, 2022, 21 (01)
  • [3] Advancements in CAR-T Therapy: A Comprehensive Review
    Tanwar, Aastha
    Targhotra, Monika
    Chauhan, Meenakshi Kanwar
    CURRENT CANCER THERAPY REVIEWS, 2024,
  • [4] CAR-T cells for hematological malignancies: exploring alternative targets
    Dotti, G.
    HUMAN GENE THERAPY, 2016, 27 (11) : A14 - A14
  • [5] Toxicities following CAR-T therapy for hematological malignancies
    Hernani, Rafael
    Benzaquen, Ana
    Solano, Carlos
    CANCER TREATMENT REVIEWS, 2022, 111
  • [6] CAR-T treatment for hematological malignancies
    Atrash, Shebli
    Bano, Kulsum
    Harrison, Bradley
    Abdallah, Al-Ola
    JOURNAL OF INVESTIGATIVE MEDICINE, 2020, 68 (05) : 956 - 964
  • [7] Current Progress in CAR-T Cell Therapy for Hematological Malignancies
    Han, Donglei
    Xu, Zenghui
    Zhuang, Yuan
    Ye, Zhenlong
    Qian, Qijun
    JOURNAL OF CANCER, 2021, 12 (02): : 326 - 334
  • [8] Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies
    Zhongfei Tao
    Zuzana Chyra
    Jana Kotulová
    Piotr Celichowski
    Jana Mihályová
    Sandra Charvátová
    Roman Hájek
    Blood Cancer Journal, 14 (1)
  • [9] CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies
    Huang, Jiawen
    Huang, Xiaobing
    Huang, Juan
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [10] The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
    Zhao, Zijun
    Chen, Yu
    Francisco, Ngiambudulu M.
    Zhang, Yuanqing
    Wu, Minhao
    ACTA PHARMACEUTICA SINICA B, 2018, 8 (04) : 539 - 551